Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase II single arm, open label, nonrandomized study. The aim of our study is to assess the
Progression Free Survival (PFS) in suboptimally cytoreduced epithelial ovarian/ primary
peritoneal/ fallopian tube cancer patients treated with the novel combination of carboplatin
every 21 days (triweekly) /weekly paclitaxel IV with pembrolizumab IV followed by maintenance
pembrolizumab IV.